Objective: Dithranol (DTH) is a well-known moiety that has long been used promisingly
to impede and treat skin disorders, particularly psoriasis. Nowadays, a rekindled interest in the use
of DTH for this disorder has been observed. Side effects associated with conventional topical formulations
of this moiety have aroused the interest of the scientific community in investigating novel
cargos of DTH for psoriasis management.
Results: Previous research has evidenced the anti-inflammatory and anti-proliferating potential of
DTH. Numerous studies have indicated that DTH inhibits polymorphonuclear (PMN) leucocyte,
modulates epidermal cell receptors and promotes anti-psoriatic action. However, some deterrent factors
like poor solubility, stability, toxicity, staining and skin irritation hamper its use as a potential
therapeutic agent. With the adoption of novel drug delivery technologies, the above mentioned inherent
limitations of DTH have been compensated to reestablish this drug moiety.
Conclusion: This article reviews novel drug delivery aspects, safety concerns, clinical evidence,
current status, and future opportunities of DTH in the management of psoriasis. Further, it will update
researchers on this promising drug moiety, which is free from systemic adverse responses in
comparison to other therapeutic molecules like steroids, for psoriasis treatment.